Spar
Antibody-Drug Conjugates
Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
- Undertittel
- The 21st Century Magic Bullets for Cancer
- Redaktør
- Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro
- Opplag
- Softcover reprint of the original 1st ed. 2015
- ISBN
- 9783319376691
- Språk
- Engelsk
- Vekt
- 310 gram
- Utgivelsesdato
- 6.10.2016
- Antall sider
- 252
